10-K: Atossa Therapeutics 2023 Annual Report: Focus on (Z)-endoxifen Clinical Trials and Strategic Investments

Atossa Therapeutics' 2023 annual report highlights ongoing clinical trials for (Z)-endoxifen and strategic investments in other healthcare opportunities, while acknowledging the need for future capital raises.

Summary

• Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for breast cancer and other breast conditions.
• Their lead drug candidate is oral (Z)-endoxifen, being developed for both prevention and treatment of breast cancer.
• The company has completed four Phase 1 and two Phase 2 clinical studies with (Z)-endoxifen and is currently investigating it in four ongoing Phase 2 trials.
• The EVANGELINE study is a randomized trial of (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with ER+/HER2breast cancer, with an expected enrollment of 180 patients.
• The Karisma-Endoxifen study is investigating (Z)-endoxifen in premenopausal women with measurable breast density, with full enrollment achieved in November 2023 and primary data expected in the second half of 2024.
• The I-SPY 2 trial is investigating (Z)-endoxifen in the neoadjuvant treatment setting for ER+ invasive breast cancer, with full enrollment of 20 participants completed in the first quarter of 2024 and data expected in the second half of 2024.
• The RECAST DCIS study is investigating (Z)-endoxifen in women diagnosed with Ductal Carcinoma In Situ (DCIS) to prevent progression to breast cancer, with the first patient dosed in February 2024.
• Atossa has a strategic research agreement with Weill Cornell Medicine to study inducing estrogen receptor expression in triple-negative breast cancer (TNBC).
• The company has invested in Dynamic Cell Therapies (DCT), a developer of CAR-T therapies, and has filed patent applications for intraductal delivery of CAR-T cells for breast cancer treatment.
• Atossa estimates the potential U.S. market for (Z)-endoxifen in breast cancer treatment and prevention to be up to $1 billion annually.
• As of December 31, 2023, the company had approximately $88.5 million in cash and cash equivalents.
• Research and development expenses for 2023 were approximately $17.3 million, compared to $15.1 million in 2022.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and strategic investments, the company's financial situation and reliance on future capital raises create uncertainty. The risks associated with drug development and regulatory approvals also temper the overall sentiment.

Positives

• Multiple Phase 2 clinical trials are underway for (Z)-endoxifen, targeting different aspects of breast cancer.
• Strategic investments in CAR-T technology and research into TNBC treatment show a commitment to innovation.
• The company has a strong intellectual property portfolio with 11 issued patents and 68 pending patent applications.
• Atossa has a significant cash position of $88.5 million, providing runway for ongoing operations.
• The company is addressing a large market with a potential value of $1 billion annually.

Negatives

• The company has a history of operating losses and expects to continue incurring losses.
• Atossa has not established an ongoing source of revenue and is dependent on raising additional capital.
• Clinical trials may face delays or fail to demonstrate efficacy and safety.
• The company relies heavily on third-party service providers for manufacturing and clinical trials.
• There is a risk of intellectual property infringement and challenges to existing patents.
• The company may not be able to obtain or maintain regulatory approvals for its products.

Risks

• The company's ability to continue as a going concern is dependent on obtaining adequate capital.
• Clinical trials may not demonstrate the efficacy and safety of (Z)-endoxifen.
• The company is dependent on third-party service providers for manufacturing and clinical trials.
• There is a risk of intellectual property infringement and challenges to existing patents.
• The company may not be able to obtain or maintain regulatory approvals for its products.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's stock price is volatile and may be affected by various factors.
• The company may experience difficulty in attracting and retaining qualified personnel.
• The company's ability to use net operating loss carryforwards and research tax credits may be limited.
• The company's Australian subsidiary may not be able to benefit from R&D rebates.

Future Outlook

The company expects to incur ongoing operating losses and will need to raise additional capital to continue its development programs. They plan to obtain additional capital resources by selling equity securities and borrowing from stockholders or others when needed. The company may also use capital resources to invest in other business opportunities in healthcare or other industries.

Management Comments

• The company's business strategy is to advance programs through clinical studies and opportunistically add programs in areas of high unmet medical need.
• Management believes they have sufficient cash on hand to fund operations for at least the next 12 months based on the current business plan.
• The company intends to use capital resources to execute on its business plan, which may include acquiring or in-licensing additional programs.
• Management believes that the potential U.S. market for (Z)-endoxifen in breast cancer treatment and prevention is up to $1 billion annually.

Industry Context

The company operates in the competitive biopharmaceutical industry, facing competition from large pharmaceutical and biotechnology companies, as well as academic and research institutions. The company is focused on developing innovative medicines for breast cancer, a significant area of unmet medical need. The company's focus on (Z)-endoxifen, a novel SERM, and its exploration of CAR-T therapies, aligns with current trends in cancer treatment.

Comparison to Industry Standards

• Atossa's focus on (Z)-endoxifen, a novel SERM, is comparable to other companies developing targeted therapies for hormone-receptor-positive breast cancer, such as Radius Health with elacestrant.
• The company's exploration of CAR-T therapies for solid tumors, particularly through intraductal delivery, is a novel approach compared to the systemic delivery methods used by companies like Novartis and Gilead in hematological malignancies.
• The company's clinical trial designs, such as the I-SPY 2 trial, are similar to other platform trials used in breast cancer research, such as those conducted by the Breast International Group (BIG).
• The company's estimated market potential of $1 billion for (Z)-endoxifen is comparable to other targeted therapies in the breast cancer space, such as CDK4/6 inhibitors like palbociclib (Ibrance) from Pfizer.
• The company's reliance on third-party manufacturers and CROs is a common practice in the biopharmaceutical industry, similar to companies like BioNTech and Moderna.
• The company's cash position of $88.5 million is relatively modest compared to larger pharmaceutical companies, but is typical for a clinical-stage biotech company.

Management Changes

Corporate Governance

Legal Proceedings

• Intas Pharmaceuticals LTD. filed a Petition for Post Grant Review (PGR) with the U.S. Patent and Trademark Office, seeking to invalidate one of the Company's issued patents.
• The company is actively contesting the PGR Petition and believes that the Patent was properly granted and is valid and enforceable.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by changes in compensation and benefits.
• Patients may benefit from the development of new treatments for breast cancer.
• Suppliers and manufacturers may be affected by the company's reliance on third-party service providers.
• Creditors may be affected by the company's financial performance and ability to repay debt.

Next Steps

• The company will continue to enroll patients in the EVANGELINE study.
• The company expects primary data from the Karisma-Endoxifen study in the second half of 2024.
• The company expects data from the I-SPY 2 trial in the second half of 2024.
• The company will continue to enroll patients in the RECAST DCIS study.
• The company will continue to evaluate its patent portfolio and file new patent applications.
• The company will continue to seek additional capital to fund its operations.

Key Dates

Keywords

(Z)-endoxifen, breast cancer, clinical trials, neoadjuvant treatment, breast density, Ductal Carcinoma In Situ, CAR-T therapy, immunotherapy, biopharmaceutical, oncology